Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.

Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examined as part of lead optimization efforts in drug discovery. Likewise, avoidance of "structural alerts" is almost a norm in drug design. However, there is a growing concern that the perceived safety hazards associated with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated. In addition, the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities. Hence, fundamental questions arise such as: When is a molecule that contains a structural alert (RM positive or negative) a cause for concern? Could the molecule in its parent form exert toxicity? Can a low dose drug candidate truly mitigate metabolism-dependent and -independent idiosyncratic toxicity risks? In an effort to address these questions, we have retrospectively examined 68 drugs (recalled or associated with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochemical characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs. Collectively, our analysis revealed that a significant proportion (∼78-86%) of drugs associated with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these molecules. In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors. Most drugs were administered at daily doses exceeding several hundred milligrams. There was no obvious link between idiosyncratic toxicity and physicochemical properties such as molecular weight, lipophilicity, etc. Approximately half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chemical architecture, and many were found to be RM-positive. Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category. However, with relatively few exceptions, the vast majority of these drugs are rarely associated with idiosyncratic toxicity, despite years of patient use. The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses. In addition, competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-positive drugs in the top 200 category. Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our analysis suggests a need for a more integrated screening paradigm for chemical hazard identification in drug discovery. Thus, in addition to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compound(s)) for lead compounds, effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compound liabilities. However, the prospective use of such data in compound selection will require further validation of the cellular assays using marketed agents. Until we gain a better understanding of the pathophysiological mechanisms associated with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the associated "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.

[1]  F. W. Madison,et al.  THE ETIOLOGY OF PRIMARY GRANULOCYTOPENIA (AGRANULOCYTIC ANGINA) , 1934 .

[2]  B. Levine STUDIES ON THE MECHANISM OF THE FORMATION OF THE PENICILLIN ANTIGEN , 1960, The Journal of experimental medicine.

[3]  B. Levine Formation of D-Penicillamine-Cysteine Mixed Disulphide by Reaction of D-Benzylpenicilloic Acid with Cystine , 1960, Nature.

[4]  Z. Óváry,et al.  STUDIES ON THE MECHANISM OF THE FORMATION OF THE PENICILLIN ANTIGEN , 1961, The Journal of experimental medicine.

[5]  Yunis Aa Chloramphenicol-induced bone marrow suppression. , 1973, JAMA.

[6]  J A Miller,et al.  Carcinogenesis by chemicals: an overview--G. H. A. Clowes memorial lecture. , 1970, Cancer research.

[7]  W. Vetter,et al.  Trimethoprim metabolites in rat, dog and man: qualitative and quantitative studies. , 1970, Arzneimittel-Forschung.

[8]  A. Yunis Chloramphenicol-induced bone marrow suppression. , 1973, Seminars in hematology.

[9]  B B Brodie,et al.  Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. , 1973, The Journal of pharmacology and experimental therapeutics.

[10]  S. Thorgeirsson,et al.  Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. , 1974, Pharmacology.

[11]  W. Potter,et al.  Hepatic necrosis caused by furosemide , 1974, Nature.

[12]  A. Frigerio,et al.  Basic metabolites of trazodone in humans. , 1974, Arzneimittel-Forschung.

[13]  B. Katchen,et al.  Disposition of a New, Nonsteroid, Antiandrogen, α,α,α-Trifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in Men Following a single Oral 200 mg Dose , 1975 .

[14]  S. Anuras,et al.  Hepatitis caused by amitriptyline therapy. , 1975, JAMA.

[15]  Z. Kopitar,et al.  [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. , 1976, Arzneimittel-Forschung.

[16]  J R Gillette,et al.  The role of biotransformation in chemical-induced liver injury. , 1976, Environmental health perspectives.

[17]  J. Timbrell,et al.  Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. , 1976, Science.

[18]  J. Boitnott,et al.  Dantrolene-associated hepatic injury. Incidence and character. , 1977, Gastroenterology.

[19]  J. Oates,et al.  Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. , 1978, The New England journal of medicine.

[20]  B. Arison,et al.  Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[21]  J. Timbrell,et al.  Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. , 1978, The Journal of pharmacology and experimental therapeutics.

[22]  L. Pohl,et al.  Study of the mechanism of metabolic activation of chloramphenicol by rat liver microsomes. , 1978, Biochemical pharmacology.

[23]  Oxidation and binding of [2-(14)C]propylthiouracil in human polymorhonuclear leukocytes. , 1979, Drug metabolism and disposition: the biological fate of chemicals.

[24]  N. Gerber,et al.  Reye-like syndrome associated with valproic acid therapy. , 1979, The Journal of pediatrics.

[25]  P. Ortiz de Montellano,et al.  Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. E. Martin,et al.  The metabolism of ranitidine in animals and man [proceedings]. , 1980, Biochemical Society transactions.

[27]  W. Kirkendall,et al.  The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. , 1980, Archives of dermatology.

[28]  M. Buytenhek,et al.  Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. , 1980, European journal of biochemistry.

[29]  [Fatal toxic hepatitis associated with administration of dantrolene (author's transl)]. , 1980, Acta neurologica Belgica.

[30]  J. Timbrell,et al.  Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. , 1980, The Journal of pharmacology and experimental therapeutics.

[31]  M. Humphrey,et al.  Species differences in the metabolism and excretion of fenclofenac. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  P. Ortiz de Montellano,et al.  Spin-trapping of free radicals formed during microsomal metabolism of ethylhydrazine and acetylhydrazine. , 1981, Biochemical and biophysical research communications.

[33]  E. Mellits,et al.  Anticonvulsant toxicity in vitro: possible role of arene oxides. , 1981, The Journal of pharmacology and experimental therapeutics.

[34]  The cellular uptake and covalent binding of nitroso-chloramphenicol. , 1981, The Journal of laboratory and clinical medicine.

[35]  J. Karliner,et al.  Metabolism of pirprofen in man, monkey, rat, and mouse. , 1982, Drug metabolism and disposition: the biological fate of chemicals.

[36]  M. Horning,et al.  Metabolism of carbamazepine. , 1982, Drug metabolism and disposition: the biological fate of chemicals.

[37]  S. Nelson,et al.  Metabolic activation and drug toxicity. , 1982, Journal of medicinal chemistry.

[38]  H. Taggart,et al.  Fatal cholestatic jaundice in elderly patients taking benoxaprofen. , 1982, British medical journal.

[39]  T. Burke,et al.  Bone marrow toxicity in vitro of chloramphenicol and its metabolites. , 1982, Toxicology and applied pharmacology.

[40]  A. Ryrfeldt,et al.  Metabolic pathways of the topical glucocorticoid budesonide in man. , 1983, Drug metabolism and disposition: the biological fate of chemicals.

[41]  A. Breckenridge,et al.  Drug protein conjugates--VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. , 1983, Biochemical pharmacology.

[42]  Arnold Th,et al.  Dantrolene sodium: urinary metabolites and hepatotoxicity. , 1983 .

[43]  D. Mansuy,et al.  Metabolic hydroxylation of the thiophene ring: isolation of 5-hydroxy-tienilic acid as the major urinary metabolite of tienilic acid in man and rat. , 1984, Biochemical pharmacology.

[44]  T. Surmann,et al.  [Cholestatic jaundice during flecainide therapy]. , 1984, Deutsche medizinische Wochenschrift.

[45]  A. Y. Lu,et al.  N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Amitriptyline-induced fulminant hepatitis. , 1984, Digestion.

[47]  J. Johnson,et al.  Biotransformation and elimination of 14C-flecainide acetate in humans. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[48]  S. Singhvi,et al.  Captopril: pharmacology, metabolism and disposition. , 1984, Drug metabolism reviews.

[49]  J. Uetrecht Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. , 1985, The Journal of pharmacology and experimental therapeutics.

[50]  J. Legrand,et al.  Ticarcillin-clavulanic acid therapy in severe infections. , 1985, Drugs under experimental and clinical research.

[51]  A. W. Macfarlane,et al.  Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine. , 1985, British medical journal.

[52]  A. Greenspon,et al.  Tocainide associated agranulocytosis. , 1985, American heart journal.

[53]  P. Nguyen-Dinh,et al.  Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. , 1985, Life sciences.

[54]  A. Salama,et al.  The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. , 1985, The New England journal of medicine.

[55]  F. Guengerich,et al.  Propane and propylene formation during the microsomal metabolism of iproniazid and isopropylhydrazine. , 1985, Life sciences.

[56]  Jerry R. Mitchell,et al.  Oxidation of hydrazine metabolites formed from isoniazid , 1985, Clinical pharmacology and therapeutics.

[57]  T. Baillie,et al.  Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[58]  J. Lockard,et al.  Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[59]  K. Neftel,et al.  Amodiaquine induced agranulocytosis and liver damage. , 1986, British medical journal.

[60]  B. Stricker,et al.  Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. , 1986, Journal of hepatology.

[61]  D. Pessayre,et al.  Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450. , 1987, Biochemical pharmacology.

[62]  G. Labbe,et al.  Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. , 1987, The Journal of pharmacology and experimental therapeutics.

[63]  A. Kitabchi,et al.  Glyburide-induced hepatitis. , 1987, Annals of internal medicine.

[64]  B. K. Park,et al.  The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. , 1987, British journal of clinical pharmacology.

[65]  D. Pessayre,et al.  Metabolic activation of the tricyclic antidepressant amineptine--II. Protective role of glutathione against in vitro and in vivo covalent binding. , 1987, Biochemical pharmacology.

[66]  A. Prox,et al.  Amitriptyline metabolites in human urine. Identification of phenols, dihydrodiols, glycols, and ketones. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[67]  [3H]chloramphenicol metabolism in human volunteer: oxamic acid as a new major metabolite. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[68]  D. Pessayre,et al.  Metabolic activation of the tricyclic antidepressant amineptine--I. Cytochrome P-450-mediated in vitro covalent binding. , 1987, Biochemical pharmacology.

[69]  T. Baillie,et al.  Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. , 1987, Science.

[70]  R. Miller METABOLISM AND DISPOSITION , 1987 .

[71]  F. Guengerich Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.

[72]  A. Taurog,et al.  Propylthiouracil and methimazole display contrasting pathways of peripheral metabolism in both rat and human. , 1988, Endocrinology.

[73]  T. Baillie,et al.  Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. , 1988, Chemical research in toxicology.

[74]  T. Baillie,et al.  Enantioselective synthesis and preliminary metabolic studies of the optical isomers of 2-n-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproic acid. , 1988, Chemical research in toxicology.

[75]  David W. Warnock,et al.  Clinical Pharmacokinetics of Ketoconazole , 1988, Clinical pharmacokinetics.

[76]  N. Kitteringham,et al.  Drug-protein conjugates--XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. , 1988, Biochemical pharmacology.

[77]  S. Spielberg,et al.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. , 1988, The Journal of clinical investigation.

[78]  A. Breckenridge,et al.  Drug-protein conjugates--XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. , 1989, Biochemical pharmacology.

[79]  R. Haddock,et al.  Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites , 1989, Acta psychiatrica Scandinavica. Supplementum.

[80]  B. Stricker,et al.  Flutamide and hepatitis. , 1989, Annals of internal medicine.

[81]  F. Guengerich Metabolism of 17 α-ethynylestradiol in humans , 1990 .

[82]  D. Morgan,et al.  Clinical Pharmacokinetics of β-Agonists , 1990 .

[83]  D. Mansuy,et al.  Oxidative activation of the thiophene ring by hepatic enzymes. Hydroxylation and formation of electrophilic metabolites during metabolism of tienilic acid and its isomer by rat liver microsomes. , 1990, Biochemical pharmacology.

[84]  W. L. Nelson,et al.  Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol. , 1990, Biochemical pharmacology.

[85]  W. F. Hoffman,et al.  Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[86]  J. Rotschafer,et al.  Clinical Pharmacokinetics of Ciprofloxacin , 1990, Clinical pharmacokinetics.

[87]  L. Benet,et al.  Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[88]  O. Nielsen,et al.  Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. , 1990, Gastroenterology.

[89]  A. Guillouzo,et al.  Use of adult human hepatocytes in primary culture for the study of clometacin-induced immunoallergic hepatitis. , 1991, Toxicology in vitro : an international journal published in association with BIBRA.

[90]  D. Mansuy,et al.  Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation. , 1991, Biochemical pharmacology.

[91]  K. Tew,et al.  Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid. , 1991, Biochemical pharmacology.

[92]  M. Miller,et al.  Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[93]  S. Singhvi,et al.  Biotransformation of pravastatin sodium in humans. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[94]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[95]  J. Uetrecht,et al.  Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[96]  K. Lasseter,et al.  The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[97]  R. Calvert,et al.  Hepatic toxicity of unmodified and time-release preparations of niacin. , 1992, The American journal of medicine.

[98]  S. Nightingale,et al.  From the Food and Drug administration. , 1990, JAMA.

[99]  K E Karlsson,et al.  A metabolic route of omeprazole involving conjugation with glutathione identified in the rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[100]  M. Pirmohamed,et al.  An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. , 1992, Biochemical pharmacology.

[101]  P L Morselli,et al.  Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. , 1992, Drug metabolism reviews.

[102]  R. Sofia,et al.  Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[103]  S. R. Howell,et al.  Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. , 1993, Xenobiotica; the fate of foreign compounds in biological systems.

[104]  C. Libersa,et al.  Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). , 1993, Life sciences.

[105]  P. Beaune,et al.  Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. , 1993, The Journal of pharmacology and experimental therapeutics.

[106]  S. Hansen,et al.  Identification of oxidation products of 5-aminosalicylic acid in faeces and the study of their formation in vitro. , 1993, Biochemical pharmacology.

[107]  P H Li,et al.  Actions of corticotropin-releasing factor or cortisol on follicle-stimulating hormone secretion by isolated pig pituitary cells. , 1993, Life sciences.

[108]  J. Taskinen,et al.  Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[109]  L. Benet,et al.  Predictability of the covalent binding of acidic drugs in man. , 1993, Life sciences.

[110]  D. Pessayre,et al.  Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. , 1994, The Journal of pharmacology and experimental therapeutics.

[111]  B. Denis,et al.  [Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]. , 1994, Gastroenterologie clinique et biologique.

[112]  R. Sampliner,et al.  Evaluation of hepatic injury arising during fluconazole therapy. , 1994, Archives of internal medicine.

[113]  T. Baillie,et al.  Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. , 1994, Chemico-biological interactions.

[114]  B. K. Park,et al.  The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine. , 1994, Journal of medicinal chemistry.

[115]  J. Miller Brief history of chemical carcinogenesis. , 1994, Cancer letters.

[116]  J. D. Proctor,et al.  A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. , 1994, JAMA.

[117]  C. Ji,et al.  Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. , 1994, The Journal of biological chemistry.

[118]  P. Beaune,et al.  Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. , 1994, Chemical research in toxicology.

[119]  B. Denis,et al.  Hépatite imputable à l'alpidem (Ananxyl®) : quatre cas dont un mortel , 1994 .

[120]  Maureen O. Gearhart Worsening of Liver Function with Fluconazole and Review of Azole Antifungal Hepatotoxicity , 1994, The Annals of pharmacotherapy.

[121]  J. Nicholson,et al.  High Resolution 1H NMR Spectroscopic Studies of the Metabolism and Excretion of Ampicillin in Rats and Amoxycillin in Rats and Man , 1994, The Journal of pharmacy and pharmacology.

[122]  J. Nicoloff,et al.  3,5,3'-Triiodothyronine (T3) sulfate: a major metabolite in T3 metabolism in man. , 1994, The Journal of clinical endocrinology and metabolism.

[123]  L. DeLeve Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. , 1994, The Journal of pharmacology and experimental therapeutics.

[124]  FDA Seeks Comments on How to Enhance Food Safety , 1994 .

[125]  Dominic P. Williams,et al.  Metabolism and bioactivation of clozapine by human liver in vitro. , 1995, The Journal of pharmacology and experimental therapeutics.

[126]  Dominic P. Williams,et al.  The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[127]  R. McClelland,et al.  Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. , 1995, Chemical Research in Toxicology.

[128]  J. Uetrecht,et al.  Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. , 1995, The Journal of pharmacology and experimental therapeutics.

[129]  A. Wood,et al.  Stereoselective disposition of carvedilol is determined by CYP2D6 , 1995, Clinical pharmacology and therapeutics.

[130]  J. Uetrecht,et al.  Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[131]  J. Cravedi,et al.  Chloramphenicol oxamylethanolamine as an end product of chloramphenicol metabolism in rat and humans: evidence for the formation of a phospholipid adduct. , 1995, Chemical research in toxicology.

[132]  D. Pessayre,et al.  Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. , 1995, Pharmacology & therapeutics.

[133]  M. Dooley,et al.  Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly , 1995, Clinical pharmacology and therapeutics.

[134]  P. Beaune,et al.  A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. , 1995, Pharmacogenetics.

[135]  A. Gaedigk,et al.  Epitope mapping studies with human anti-cytochrome P450 3A antibodies. , 1996, Molecular pharmacology.

[136]  H. Enevoldsen,et al.  Nortriptyline-induced hepatic failure. , 1996, Therapeutic drug monitoring.

[137]  G. Bennett,et al.  Protein-reactive metabolites of carbamazepine in mouse liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[138]  D. Mansuy,et al.  Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. , 1996, Biochemical and biophysical research communications.

[139]  T. Watanabe,et al.  Absorption, metabolism and excretion of tamsulosin hydrochloride in man. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[140]  M. Pirmohamed,et al.  Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. , 1997, The Journal of pharmacology and experimental therapeutics.

[141]  D. Fish,et al.  The Clinical Pharmacokinetics of Levofloxacin , 1997, Clinical pharmacokinetics.

[142]  N. Davies,et al.  Clinical Pharmacokinetics of Naproxen , 1997, Clinical pharmacokinetics.

[143]  D. Acosta,et al.  N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. , 1997, Toxicology.

[144]  R R Miller,et al.  Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[145]  K. Wilner,et al.  Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[146]  J. Volpicelli,et al.  Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. , 1997, Alcoholism: Clinical and Experimental Research.

[147]  D. Acosta,et al.  Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[148]  M. Pirmohamed,et al.  Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[149]  G. Sachs,et al.  Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents* , 1997, The Journal of Biological Chemistry.

[150]  C. Cywin,et al.  Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. , 1997, Journal of medicinal chemistry.

[151]  J. Uetrecht,et al.  Structural features associated with reactive metabolite formation in clozapine analogues. , 1997, Chemico-biological interactions.

[152]  R. Barbhaiya,et al.  Clinical Pharmacokinetics of Nefazodone , 1997, Clinical pharmacokinetics.

[153]  D. Kempf,et al.  Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[154]  C. D. Thompson,et al.  Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. , 1997, Chemical research in toxicology.

[155]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[156]  A L Burlingame,et al.  Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Studies By tandem mass spectrometry. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[157]  L. Friedhoff,et al.  Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. , 1998, British journal of clinical pharmacology.

[158]  L. Marnett,et al.  Aspirin-like molecules that covalently inactivate cyclooxygenase-2. , 1998, Science.

[159]  J A Miller,et al.  The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates. , 1998, Drug metabolism reviews.

[160]  P. Ward,et al.  Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802 , 1999, Clinical pharmacokinetics.

[161]  J. Reid,et al.  Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[162]  B. Luxon,et al.  Nefazodone-induced liver failure: report of three cases. , 1999 .

[163]  M. Çetin,et al.  Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma , 1999, Human & experimental toxicology.

[164]  J. Rosenborg,et al.  Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[165]  A. Mutlib,et al.  Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[166]  B. Luxon,et al.  Nefazodone-Induced Liver Failure: Report of Three Cases , 1999, Annals of Internal Medicine.

[167]  Improvement of Flutamide-induced hepatotoxicity by Ursodeoxycholic acid in male rats. , 1999 .

[168]  C. D. Thompson,et al.  Quantification in Patient Urine Samples of Felbamate and Three Metabolites: Acid Carbamate and Two Mercapturic Acids , 1999, Epilepsia.

[169]  R. Gasser,et al.  Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. , 1999, British journal of clinical pharmacology.

[170]  D. Mansuy,et al.  Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. , 1999, Chemical research in toxicology.

[171]  K. Kakehi,et al.  In vitro regioselective stability of beta-1-O- and 2-O-acyl glucuronides of naproxen and their covalent binding to human serum albumin. , 1999, Journal of pharmaceutical sciences.

[172]  H. Stass,et al.  Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. , 1999, The Journal of antimicrobial chemotherapy.

[173]  T. Macgregor,et al.  Disposition and biotransformation of the antiretroviral drug nevirapine in humans. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[174]  J. Uetrecht,et al.  Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. , 1999, The Journal of pharmacology and experimental therapeutics.

[175]  S. Knowles,et al.  Anticonvulsant Hypersensitivity Syndrome , 1999, Drug safety.

[176]  U. Christians,et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[177]  C. Sempoux,et al.  HLA association of amoxicillin-clavulanate--induced hepatitis. , 1999, Gastroenterology.

[178]  T. Vree,et al.  High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[179]  J. Uetrecht,et al.  Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. , 1999, The Journal of pharmacology and experimental therapeutics.

[180]  J. Tomashefski,et al.  Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. , 1999, Archives of pathology & laboratory medicine.

[181]  P. Janicak,et al.  Quantitation of clonazepam and its major metabolite 7-aminoclonazepam in hair. , 2000, Journal of analytical toxicology.

[182]  S. Wong,et al.  The role of mitochondrial injury in bromobenzene and furosemide induced hepatotoxicity. , 2000, Toxicology letters.

[183]  S. Schenker,et al.  Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity , 2000, American Journal of Gastroenterology.

[184]  M. Pirmohamed,et al.  Metabolism of lamotrigine to a reactive arene oxide intermediate. , 2000, Chemical research in toxicology.

[185]  J. Uetrecht,et al.  Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[186]  P. Woster,et al.  A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. , 2000, The Journal of investigative dermatology.

[187]  K. Knights,et al.  In vitro covalent binding of nafenopin-CoA to human liver proteins. , 2000, Toxicology and applied pharmacology.

[188]  M Antonsson,et al.  Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[189]  R. Schleimer,et al.  A Mass Balance Study to Evaluate the Biotransformation and Excretion of [14C]‐Triamcinolone Acetonide following Oral Administration , 2000, Journal of clinical pharmacology.

[190]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[191]  Jürg Reichen,et al.  The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions , 2001, Clinical pharmacology and therapeutics.

[192]  R Bracher,et al.  Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. , 2001, Journal of hepatology.

[193]  Hepatotoxicity Associated with Carvedilol , 2001, The Annals of pharmacotherapy.

[194]  Y. Sun,et al.  Kinetics of beta-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumoniae. Involvement of acylation and deacylation in beta-lactam resistance. , 2001, The Journal of biological chemistry.

[195]  T. Baillie,et al.  Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. , 2001, Chemical research in toxicology.

[196]  M. G. Johnson,et al.  Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[197]  C. Funk,et al.  Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. , 2001, Molecular pharmacology.

[198]  D. Pessayre,et al.  Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. , 2001, Journal of hepatology.

[199]  D. Pessayre,et al.  Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. , 2001, The Journal of pharmacology and experimental therapeutics.

[200]  T. Baillie,et al.  Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[201]  C. McClintock,et al.  Hepatotoxicity after Short-Term Trazodone Therapy , 2001, The Annals of pharmacotherapy.

[202]  I. Bjørnsdottir,et al.  Chemical reactivity of the naproxen acyl glucuronide and the naproxen coenzyme A thioester towards bionucleophiles. , 2002, Journal of pharmaceutical and biomedical analysis.

[203]  C. D. Thompson,et al.  Mechanisms of idiosyncratic drug reactions: the case of felbamate. , 2002, Chemico-biological interactions.

[204]  Jeffrey C Stevens,et al.  Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[205]  M. Cazzola,et al.  Clinical Pharmacokinetics of Salmeterol , 2002, Clinical Pharmacokinetics.

[206]  J. Walsh,et al.  The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. , 2002, Chemico-biological interactions.

[207]  J L Sussman,et al.  Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. , 2002, Biochemistry.

[208]  R. Iannucci,et al.  Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[209]  P. Hollenberg,et al.  Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. , 2002, The Journal of pharmacology and experimental therapeutics.

[210]  M. Maftouh,et al.  Structure and stereochemistry of the active metabolite of clopidogrel. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[211]  J. Rimmer,et al.  β‐Lactam allergenic determinants: fine structural recognition of a cross‐reacting determinant on benzylpenicillin and cephalothin , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[212]  T. Baillie,et al.  Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. , 2002, Chemical research in toxicology.

[213]  J. Ware,et al.  Mechanistic studies on the bioactivation of diclofenac: identification of diclofenac-S-acyl-glutathione in vitro in incubations with rat and human hepatocytes. , 2003, Chemical research in toxicology.

[214]  John-Michael Sauer,et al.  Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[215]  I. Bjørnsdottir,et al.  Identification of coenzyme A-related tolmetin metabolites in rats: relationship with reactive drug metabolites , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[216]  T. Gillespie,et al.  Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[217]  B. Schmidt,et al.  Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. , 2003, Journal of medicinal chemistry.

[218]  T. Macdonald,et al.  In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. , 2003, Chemical research in toxicology.

[219]  H. Lennernäs Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.

[220]  D. Pessayre,et al.  Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug‐induced steatosis in mice , 2003, Hepatology.

[221]  J. Borlak,et al.  Verapamil: identification of novel metabolites in cultures of primary human hepatocytes and human urine by LC-MS n and LC-NMR , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[222]  M. Grillo,et al.  Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[223]  R. Rodriguez,et al.  Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[224]  M. Pirmohamed,et al.  Characterization of drug-specific T cells in lamotrigine hypersensitivity. , 2003, The Journal of allergy and clinical immunology.

[225]  A. Kalgutkar,et al.  Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[226]  M. Grant,et al.  The toxicity of opiates and their metabolites in HepG2 cells. , 2003, Chemico-biological interactions.

[227]  A. Kalgutkar,et al.  In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[228]  T. Baillie,et al.  Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. , 2003, Chemical research in toxicology.

[229]  A. Schapira,et al.  Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells , 2004, Neuropharmacology.

[230]  M. Schulz,et al.  The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment , 2004, European Journal of Clinical Pharmacology.

[231]  Christian Skonberg,et al.  In vitro reactivity of carboxylic acid-CoA thioesters with glutathione. , 2004, Chemical research in toxicology.

[232]  S. Hervé,et al.  Acute hepatitis due to buprenorphine administration , 2004, European journal of gastroenterology & hepatology.

[233]  J. Brouwers,et al.  Leflunomide for the Treatment of Rheumatoid Arthritis in Clinical Practice , 2004, Drug safety.

[234]  U. Breyer‐Pfaff The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in Man , 2004, Drug metabolism reviews.

[235]  J. Bolton,et al.  Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. , 2004, Chemical research in toxicology.

[236]  J. Uetrecht,et al.  Animal models of idiosyncratic drug reactions. , 2004, Chemico-biological interactions.

[237]  F. Azam,et al.  A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. , 2004, Chemical research in toxicology.

[238]  G. Sachs,et al.  Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. , 2004, Journal of the American Chemical Society.

[239]  In vitro‐in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude , 2004 .

[240]  C. Rordorf,et al.  Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[241]  S. Belknap,et al.  Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by Non–HIV-Infected Individuals , 2004, Journal of acquired immune deficiency syndromes.

[242]  Philip C Smith,et al.  Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo. , 2005, Biochemical pharmacology.

[243]  F. Lombardo,et al.  BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4 , 2005, Drug Metabolism and Disposition.

[244]  T. Baillie,et al.  Minimizing the potential for metabolic activation as an integral part of drug design. , 2005, Current opinion in drug discovery & development.

[245]  M. Popović,et al.  A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. , 2005, Chemical research in toxicology.

[246]  J. Gillespie,et al.  Effect of Tadalafil on Cytochrome P450 3A4–mediated Clearance: Studies in Vitro and in Vivo , 2005, Clinical pharmacology and therapeutics.

[247]  B. Goichot,et al.  Antithyroid drugs , 2005, The New England journal of medicine.

[248]  G. Nappi,et al.  Two patients with COMT inhibitor–induced hepatic dysfunction and UGT1A9 genetic polymorphism , 2005, Neurology.

[249]  Munir Pirmohamed,et al.  The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.

[250]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[251]  Xiaoyan Chen,et al.  Metabolism of pantoprazole involving conjugation with glutathione in rats , 2005, The Journal of pharmacy and pharmacology.

[252]  A. Kalgutkar,et al.  Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. , 2005, Chemico-biological interactions.

[253]  William M. Lee,et al.  Acute Liver Failure Due To Amoxicillin and Amoxicillin/Clavulanate , 2005, Digestive Diseases and Sciences.

[254]  A. Kalgutkar,et al.  Minimising the potential for metabolic activation in drug discovery , 2005, Expert opinion on drug metabolism & toxicology.

[255]  J. Wingard,et al.  Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[256]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[257]  J. Waring,et al.  Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin , 2005, Hepatology.

[258]  In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. , 2005, Chemical research in toxicology.

[259]  Gildas Bertho,et al.  First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives. , 2005, Biochemical and biophysical research communications.

[260]  P. Zbinden,et al.  METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS , 2005, Drug Metabolism and Disposition.

[261]  Ping Zhao,et al.  HUMAN IN VITRO GLUTATHIONYL AND PROTEIN ADDUCTS OF CARBAMAZEPINE-10,11-EPOXIDE, A STABLE AND PHARMACOLOGICALLY ACTIVE METABOLITE OF CARBAMAZEPINE , 2005, Drug Metabolism and Disposition.

[262]  A. Kalgutkar,et al.  A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. , 2006, Chemical research in toxicology.

[263]  G. Kearns,et al.  BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION , 2006, Drug Metabolism and Disposition.

[264]  W. Thormann,et al.  Analysis of lorazepam and its 30-glucuronide in human urine by capillary electrophoresis: evidence for the formation of two distinct diastereoisomeric glucuronides. , 2006, Journal of separation science.

[265]  Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. , 2006, AIDS.

[266]  S. Krähenbühl,et al.  Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone Derivatives , 2006, Journal of Pharmacology and Experimental Therapeutics.

[267]  A. Kalgutkar,et al.  Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[268]  T. Hartung,et al.  Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. , 2006, Chemical research in toxicology.

[269]  John Cl Erve,et al.  Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology , 2006, Expert opinion on drug metabolism & toxicology.

[270]  P. Milkiewicz,et al.  Oxidative stress induces internalization of the bile salt export pump, Bsep, and bile salt secretory failure in isolated rat hepatocyte couplets: a role for protein kinase C and prevention by protein kinase A. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[271]  P. Neuvonen,et al.  Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.

[272]  David C Evans,et al.  EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS , 2006, Drug Metabolism and Disposition.

[273]  Pascual Ferrara,et al.  The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[274]  H. Lennernäs,et al.  FLUTAMIDE METABOLISM IN FOUR DIFFERENT SPECIES IN VITRO AND IDENTIFICATION OF FLUTAMIDE METABOLITES IN HUMAN PATIENT URINE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY , 2006, Drug Metabolism and Disposition.

[275]  G. Hochhaus,et al.  METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES , 2006, Drug Metabolism and Disposition.

[276]  Y. Masubuchi,et al.  Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. , 2006, Toxicology.

[277]  M. Nobilis,et al.  High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. , 2006, Journal of chromatography. A.

[278]  Luca Testa,et al.  The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile , 2007, Expert opinion on drug safety.

[279]  D. Dalvie,et al.  Identification of a Novel Glutathione Conjugate of Flutamide in Incubations with Human Liver Microsomes , 2007, Drug Metabolism and Disposition.

[280]  T. Macgregor,et al.  Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir , 2007, Antimicrobial Agents and Chemotherapy.

[281]  P. Zhao,et al.  Identification of primary and sequential bioactivation pathways of carbamazepine in human liver microsomes using liquid chromatography/tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.

[282]  S. Russell Carnitine as an antidote for acute valproate toxicity in children , 2007, Current opinion in pediatrics.

[283]  Yvonne Will,et al.  The significance of mitochondrial toxicity testing in drug development. , 2007, Drug discovery today.

[284]  L. Benet,et al.  Studies on the Metabolism of Tolmetin to the Chemically Reactive Acyl-Coenzyme A Thioester Intermediate in Rats , 2007, Drug Metabolism and Disposition.

[285]  P. Meier,et al.  Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury , 2007, Pharmacogenetics and genomics.

[286]  N. Chalasani,et al.  Lipid-lowering agents that cause drug-induced hepatotoxicity. , 2007, Clinics in liver disease.

[287]  A. Kalgutkar,et al.  NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine. , 2007, Chemical research in toxicology.

[288]  Kazuya Maeda,et al.  Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor , 2007, Drug Metabolism and Disposition.

[289]  R. Remmel,et al.  Conjugative Metabolism of Drugs , 2007 .

[290]  Takashi Usui,et al.  Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance–associated protein 2 , 2007, Biopharmaceutics & drug disposition.

[291]  N. Masubuchi,et al.  Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. , 2007, Chemical research in toxicology.

[292]  D. A. Williams,et al.  Identification and characterization of two chloramphenicol glucuronides from the in vitro glucuronidation of chloramphenicol in human liver microsomes , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[293]  G. Gervasini,et al.  Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. , 2007, Drug metabolism letters.

[294]  P. Hollenberg,et al.  The Inactivation of Cytochrome P450 3A5 by 17α-Ethynylestradiol Is Cytochrome b5-Dependent: Metabolic Activation of the Ethynyl Moiety Leads to the Formation of Glutathione Conjugates, a Heme Adduct, and Covalent Binding to the Apoprotein , 2007, Journal of Pharmacology and Experimental Therapeutics.

[295]  Jie Chen,et al.  Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap. , 2007, Rapid communications in mass spectrometry : RCM.

[296]  P. Preziosi Isoniazid: metabolic aspects and toxicological correlates. , 2007, Current drug metabolism.

[297]  G. S. Walker,et al.  Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy. , 2007, Chemical research in toxicology.

[298]  Mark D. Johnson,et al.  Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. , 2007, Chemical research in toxicology.

[299]  H. Fujita,et al.  Silicon Nanotweezers With Subnanometer Resolution for the Micromanipulation of Biomolecules , 2008, Journal of Microelectromechanical Systems.

[300]  T. Baillie,et al.  In Vitro Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations , 2008, Drug Metabolism And Disposition.

[301]  M. Monshouwer,et al.  Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase. , 2008, Chemical research in toxicology.

[302]  J. Xu,et al.  In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[303]  Leonard Buckbinder,et al.  Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation. , 2008, Bioorganic & medicinal chemistry letters.

[304]  B. Roy,et al.  Pharmacogenomics of anti-TB drugs-related hepatotoxicity. , 2008, Pharmacogenomics.

[305]  R. Reeves,et al.  Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia , 2008, Clinical pharmacokinetics.

[306]  S. Kennedy,et al.  The hepatic safety profile of duloxetine: a review. , 2008, Expert opinion on drug metabolism & toxicology.

[307]  Interaction of the Electrophilic Ketoprofenyl-Glucuronide and Ketoprofenyl-Coenzyme A Conjugates with Cytosolic Glutathione S-Transferases , 2008, Drug Metabolism and Disposition.

[308]  N. Vermeulen,et al.  Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s. , 2008, Chemical research in toxicology.

[309]  Review: hepatotoxicity and EGFR inhibition. , 2008, Clinical advances in hematology & oncology : H&O.

[310]  R Scott Obach,et al.  In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam. , 2008, Chemical research in toxicology.

[311]  J. Waring,et al.  Trovafloxacin-Induced Gene Expression Changes in Liver-Derived in Vitro Systems: Comparison of Primary Human Hepatocytes to HepG2 Cellss⃞ , 2008, Drug Metabolism and Disposition.

[312]  Daniel C Liebler,et al.  Protein damage by reactive electrophiles: targets and consequences. , 2008, Chemical research in toxicology.

[313]  R. Andrade,et al.  Glutathione S‐transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug‐induced liver injury , 2008, Hepatology.

[314]  Christian Skonberg,et al.  Metabolic activation of carboxylic acids. , 2008, Expert opinion on drug metabolism & toxicology.

[315]  Human N-acetyltransferases and drug-induced hepatotoxicity. , 2008, Current drug metabolism.

[316]  Angus N R Nedderman,et al.  Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. , 2008, British journal of clinical pharmacology.

[317]  T. Macdonald,et al.  In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity. , 2008, Chemical research in toxicology.

[318]  R. Obach,et al.  Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. , 2008, Chemical research in toxicology.

[319]  Fatal amiodarone-induced hepatotoxicity: a case report and literature review. , 2008, International journal of clinical pharmacology and therapeutics.

[320]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[321]  J. Bauman,et al.  Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug , 2008, Drug Metabolism and Disposition.

[322]  R Scott Obach,et al.  Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. , 2008, Chemical research in toxicology.

[323]  Angus Nedderman,et al.  In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery. , 2008, Current drug metabolism.

[324]  Li Ma,et al.  Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. , 2008, Chemico-biological interactions.

[325]  A. D. Rodrigues,et al.  Detection of Novel Reactive Metabolites of Trazodone: Evidence for CYP2D6-Mediated Bioactivation of m-Chlorophenylpiperazine , 2008, Drug Metabolism and Disposition.

[326]  H. Sasaki,et al.  Simultaneous determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human serum by capillary zone electrophoresis. , 2008, Journal of pharmaceutical and biomedical analysis.

[327]  Wei Yang Lu,et al.  Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine , 2008, Drug Metabolism and Disposition.

[328]  S. Mohiuddin,et al.  Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy , 2009, Expert opinion on drug metabolism & toxicology.

[329]  H. Jones,et al.  Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. , 2009, Clinical chemistry.

[330]  Jennifer Q. Dong,et al.  Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes , 2009, Drug Metabolism and Disposition.

[331]  W. Humphreys,et al.  In vitro screening of 50 highly prescribed drugs for thiol adduct formation--comparison of potential for drug-induced toxicity and extent of adduct formation. , 2009, Chemical research in toxicology.

[332]  P. Tulkens,et al.  Terms and Conditions for Use of Pdf , 2022 .

[333]  Osamu Okazaki,et al.  A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding , 2009, Drug Metabolism and Disposition.

[334]  P. Ganey,et al.  Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[335]  Y. Will,et al.  The role of mitochondrial dysfunction and drug safety. , 2009, IDrugs : the investigational drugs journal.

[336]  A. Parkinson,et al.  In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran , 2009, Drug Metabolism and Disposition.

[337]  K. Srivenugopal,et al.  Does aspirin acetylate multiple cellular proteins? (Review). , 2009, Molecular medicine reports.

[338]  A. Kalgutkar,et al.  Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. , 2009, Chemical research in toxicology.

[339]  M. Cameron,et al.  Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways , 2009, Drug Metabolism and Disposition.

[340]  Nigel Greene,et al.  Early toxicity screening strategies. , 2009, Current opinion in drug discovery & development.

[341]  N. Trudgill,et al.  Patients with prostate cancer are less likely to develop oesophageal adenocarcinoma: could androgens have a role in the aetiology of oesophageal adenocarcinoma? , 2009, Cancer Causes & Control.

[342]  G. Mannens,et al.  Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects , 2009, Drug Metabolism and Disposition.

[343]  Mechanisms of Drug Hepatotoxicity in Man: Novel Insights Provided by the THLE-CYP Cell Panel , 2009 .

[344]  M. Cameron,et al.  Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. , 2009, Chemical research in toxicology.

[345]  Tadao Yoshioka,et al.  Structure-activity relationships for the degradation reaction of 1-beta-O-acyl glucuronides. Part 3: Electronic and steric descriptors predicting the reactivity of aralkyl carboxylic acid 1-beta-O-acyl glucuronides. , 2009, Chemical research in toxicology.

[346]  A. Kalgutkar,et al.  Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity? , 2009, Chemistry & biodiversity.

[347]  S. Wolverton,et al.  Moxifloxacin-induced drug hypersensitivity syndrome with features of toxic epidermal necrolysis. , 2009, Journal of drugs in dermatology : JDD.

[348]  Vijay T. Ahuja,et al.  A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. , 2009, Journal of medicinal chemistry.

[349]  B. K. Park,et al.  Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. , 2009, Chemical research in toxicology.

[350]  梅澤 宏亘 Determination of diazepam and its metabolites in human urine by liquid chromatography/tandem mass spectrometry using a hydrophilic polymer column , 2009 .

[351]  D. Mansuy,et al.  Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. , 2009, Chemical research in toxicology.

[352]  Masashi Yabuki,et al.  Evaluation of the Potential for Drug-Induced Liver Injury Based on in Vitro Covalent Binding to Human Liver Proteins , 2009, Drug Metabolism and Disposition.

[353]  Differential Modulation of Farnesoid X Receptor Signaling Pathway by the Thiazolidinediones , 2009, Journal of Pharmacology and Experimental Therapeutics.

[354]  Hiroyuki Hirano,et al.  Technical Pitfalls and Improvements for High-speed Screening and QSAR Analysis to Predict Inhibitors of the Human Bile Salt Export Pump (ABCB11/BSEP) , 2009, The AAPS Journal.

[355]  D. Price,et al.  Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients , 2009, Expert opinion on drug metabolism & toxicology.

[356]  Yuan Chen,et al.  Metabolic Activation of Nevirapine in Human Liver Microsomes: Dehydrogenation and Inactivation of Cytochrome P450 3A4 , 2009, Drug Metabolism and Disposition.

[357]  S. Parapini,et al.  Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine. , 2009, Journal of medicinal chemistry.

[358]  Jianwen Fang,et al.  Filling and mining the reactive metabolite target protein database. , 2009, Chemico-biological interactions.

[359]  D. Dalvie,et al.  Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts. , 2009, Chemical research in toxicology.

[360]  Jiri Aubrecht,et al.  Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. , 2010, Toxicology letters.

[361]  Nigel Greene,et al.  Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. , 2010, Bioorganic & medicinal chemistry letters.

[362]  Hao Chen,et al.  Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. , 2010, Chemical research in toxicology.

[363]  Investigation of bioactivation of ticlopidine using linear ion trap/orbitrap mass spectrometry and an improved mass defect filtering technique. , 2010, Chemical research in toxicology.

[364]  M. Cameron,et al.  Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile , 2010, Drug Metabolism and Disposition.

[365]  J. Polli,et al.  Uptake of pramipexole by human organic cation transporters. , 2010, Molecular pharmaceutics.

[366]  Cynthia A Afshari,et al.  Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[367]  R. Hui,et al.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. , 2010, Pharmacogenomics.

[368]  S. Mallal,et al.  Pharmacogenetics of drug hypersensitivity. , 2010, Pharmacogenomics.

[369]  J. Erve,et al.  Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs. , 2010, Chemical research in toxicology.

[370]  Q. Zeng,et al.  Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screening. , 2010, Chemical research in toxicology.

[371]  A. Daly Drug-induced liver injury: past, present and future. , 2010, Pharmacogenomics.

[372]  Dominic P. Williams,et al.  Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass Spectrometries , 2010, Drug Metabolism and Disposition.

[373]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[374]  Dominic P. Williams,et al.  Acyl glucuronides: the good, the bad and the ugly. , 2010, Biopharmaceutics & drug disposition.

[375]  I. Wilson,et al.  Integrated HPLC-MS and 1H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[376]  R. Bonomo,et al.  Three Decades of β-Lactamase Inhibitors , 2010, Clinical Microbiology Reviews.

[377]  T. Woolf,et al.  Metabolic disposition of the non-steroidal anti-inflammatory agent isoxicam in man , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[378]  Dean G. Brown,et al.  Identification of Multiple Glutathione Conjugates of 8-Amino- 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline maleate (Nomifensine) in Liver Microsomes and Hepatocyte Preparations: Evidence of the Bioactivation of Nomifensine , 2010, Drug Metabolism and Disposition.

[379]  E. Chan,et al.  Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib , 2010, Molecular Pharmacology.

[380]  G. Bruin,et al.  Pharmacokinetics, Metabolism, and Disposition of Deferasirox in β-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State , 2010, Drug Metabolism and Disposition.

[381]  P. Meier,et al.  Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. , 2010, Seminars in liver disease.

[382]  Atsushi Kurihara,et al.  Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans , 2010, Journal of clinical pharmacology.

[383]  B. Stieger Role of the bile salt export pump, BSEP, in acquired forms of cholestasis , 2010, Drug metabolism reviews.

[384]  R. Ward,et al.  The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. , 2010, Chemical research in toxicology.

[385]  F. Beland,et al.  Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity. , 2010, Chemical research in toxicology.

[386]  Nigel Greene,et al.  Developing structure-activity relationships for the prediction of hepatotoxicity. , 2010, Chemical research in toxicology.

[387]  L. Melvin,et al.  Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. , 2010, Canadian journal of physiology and pharmacology.

[388]  E. Mocaer,et al.  Metabolism of amineptine in rat, dog and man , 1990, European Journal of Drug Metabolism and Pharmacokinetics.

[389]  A. Kalgutkar,et al.  Intrinsic electrophilicity of a 4-substituted-5-cyano-6-(2-methylpyridin-3-yloxy)pyrimidine derivative: structural characterization of glutathione conjugates in vitro. , 2011, Chemical research in toxicology.

[390]  H. Conjeevaram,et al.  Clinical and histopathologic features of fluoroquinolone-induced liver injury. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[391]  Yan Li,et al.  Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.

[392]  Ian D. Wilson,et al.  Managing the challenge of chemically reactive metabolites in drug development , 2011, Nature Reviews Drug Discovery.

[393]  B. Peng,et al.  Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects , 2011, Drug Metabolism and Disposition.

[394]  Dennis A. Smith,et al.  Multiple factors govern the association between pharmacology and toxicity in a class of drugs: toward a unification of class effect terminology. , 2011, Chemical research in toxicology.

[395]  K. King,et al.  HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.